Article | January 31, 2019

With Investors' Eyes On Biotechs, Biotechs Must Keep Their Eyes On Transparency

Source: Citeline

By Darcy Grabenstein

dollar_money_pillls_finance_450x300

If recent pharmaceutical mergers and acquisitions are any indication, 2019 is poised to marked by industry deal-making. Earlier this month, the J.P. Morgan Healthcare Conference coincided with Eli Lilly & Co.’s $8 billion acquisition of Loxo Oncology Inc. The news came on the heels of the $74 billion merger of Bristol-Myers Squibb and Celgene, and the $5.1 billion acquisition of Tesaro Inc. by GlaxoSmithKline PLC.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader